Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
Số trang: 7
Loại file: pdf
Dung lượng: 968.75 KB
Lượt xem: 8
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Although the standard therapy for advanced-stage hepatocellular carcinoma (HCC) is systemic chemotherapy, the combination of atezolizumab and bevacizumab (atezo+bev) with a high objective response rate may lead to conversion to resection in patients with initially unresectable HCC. This study aims to evaluate the efficacy of atezo+bev in achieving conversion surgery and prolonged progression-free survival (PFS) for initially unresectable HCC.
Nội dung trích xuất từ tài liệu:
Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
Nội dung trích xuất từ tài liệu:
Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Hepatocellular carcinoma Advanced stage Immune checkpoint inhibitor Prolonged progression-free survivalTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
13 trang 38 0 0
-
12 trang 38 0 0